Diabetic Macular Edema – Pipeline Review, H2 2018
- Pages: 231
- Published: July 2018
- Report Code: GMDHC10643IDB
Global Markets Direct’s, ‘Diabetic Macular Edema – Pipeline Review, H2 2018’, provides an overview of the Diabetic Macular Edema pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
– The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
– The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abpro
Aciont Inc
Acucela Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allergan Plc
Allgenesis Biotherapeutics Inc
Ampio Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Cell Medica Ltd
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
Daiichi Sankyo Co Ltd
Elasmogen Ltd
Exonate Ltd
EyeGate Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Formycon AG
Gene Signal International SA
Genmab A/S
Graybug Vision Inc
Isarna Therapeutics GmbH
Kalvista Pharmaceuticals Inc
Kowa Co Ltd
Lupin Ltd
Mabion SA
Momenta Pharmaceuticals Inc
Novartis AG
Ocular Therapeutix Inc
Oculis ehf
OcuNexus Therapeutics Inc
Ohr Pharmaceutical Inc
Pfizer Inc
Profarma
Protheragen Inc
Regeneron Pharmaceuticals Inc
Rezolute Inc
SciFluor Life Sciences LLC
Senju Pharmaceutical Co Ltd
Stealth BioTherapeutics Inc
ThromboGenics NV
Unity Biotechnology Inc
Verseon Corp
Xbrane Biopharma AB
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.